InDex Pharmaceuticals Holding AB (publ) published its interim report Q2 for January-June 2021 on August 25, 2021 at 08:00 a.m. CEST.

Our upcoming Phase III study CONCLUDE

Have a look at InDex’s corporate presentation

CEO corner

Learn more about Peter Zerhouni, our CEO

InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis

Proud partner of: